Mandate

Vinge advises Active Biotech in its new issue

April 06, 2009

Vinge has advised Active Biotech in its new issue of shares subject to pre-emption rights for the existing shareholders. Under the new issue, which is underwritten in its entirety by the principal shareholders MGA Holding and Nordstjernan, Active Biotech receives approximately SEK 256 million.

Vinge’s team was led by Erik Sjöman who was assisted by, among others, associates Christian Lindhé, Karolina Tjärnberg Jansson and Maria Doeser (tax law advice).

Related

Vinge has advised Northmill Group AB in connection with the issuance of tier 2 capital bonds (T2)

Vinge has advised Northmill Group AB in connection with its successful issuance of SEK 150 million tier 2 capital bonds (T2) with a floating rate interest of 3-month STIBOR + 475 basis points.
September 11, 2026

Vinge advises IK Partners and Francks Kylindustri in connection with the acquisition of Helsingborgs Kylteknik

Vinge has advised IK Partners and its portfolio company Francks Kylindustri in connection with the acquisition of Helsingborgs Kylteknik, a company specialising in refrigeration technology and refrigeration services in southern Sweden. The acquisition strengthens Francks Kylindustri’s position in southern Sweden and broadens the group’s offering within the refrigeration industry.
September 11, 2026

Vinge advises the sellers of Berg Propulsion

Vinge has advised the sellers in connection with the sale of Berg Propulsion to Kongsberg Maritime.
September 10, 2026